Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045695 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
A Phase 2 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00045695 is a Phase 2 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 27 participants.
The verdict
NCT00045695, a Phase 2 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have untreated or relapsed Waldenstrom's macroglobulinemia.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2002-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045695
The ClinicalTrials.gov registry entry for NCT00045695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00045695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045695 about?
NCT00045695 is a clinical study titled "Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia". RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have untreated or relapsed Waldenstrom's macroglobulinemia.
What is the current status of trial NCT00045695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2002-08. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00045695?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00045695?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.